WO2003037397A2 - Greffes a stent tubulaire extensible radialement eluant les medicaments - Google Patents

Greffes a stent tubulaire extensible radialement eluant les medicaments Download PDF

Info

Publication number
WO2003037397A2
WO2003037397A2 PCT/US2002/035065 US0235065W WO03037397A2 WO 2003037397 A2 WO2003037397 A2 WO 2003037397A2 US 0235065 W US0235065 W US 0235065W WO 03037397 A2 WO03037397 A2 WO 03037397A2
Authority
WO
WIPO (PCT)
Prior art keywords
carbons
drug eluting
stented graft
stent
eluting stented
Prior art date
Application number
PCT/US2002/035065
Other languages
English (en)
Other versions
WO2003037397A3 (fr
Inventor
Donald T. Shannon
Original Assignee
Edwards Lifesciences Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/997,829 external-priority patent/US20020042645A1/en
Application filed by Edwards Lifesciences Corporation filed Critical Edwards Lifesciences Corporation
Priority to CA2465517A priority Critical patent/CA2465517C/fr
Priority to JP2003539736A priority patent/JP2005507710A/ja
Priority to EP02780558A priority patent/EP1439868A2/fr
Publication of WO2003037397A2 publication Critical patent/WO2003037397A2/fr
Publication of WO2003037397A3 publication Critical patent/WO2003037397A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A61F2002/075—Stent-grafts the stent being loosely attached to the graft material, e.g. by stitching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Definitions

  • This invention pertains generally to medical devices and their methods of manufacture, and more particularly to drug eluting tubular grafts having radially expandable stents for implantation in a cavities or passageways (e.g., ducts or blood vessels) of the body, wherein the stents have polymer coats that possess the capability to release drugs.
  • A. Stents The prior art includes a number of radially expandable stents which may be initially deployed in a radially collapsed state suitable for transluminal insertion via a delivery catheter, and subsequently transitioned to a radially expanded state whereby the stent will contact and engage the surrounding wall or the anatomical duct or body cavity within which the stent has been positioned.
  • Such stents have been used to support and maintain the patency of blood vessel lumens (e.g., as an adjuvant to balloon angioplasty) and to structurally support and/or anchor other apparatus, such as a tubular endovascuiar grafts, at desired locations within a body cavity or passageway.
  • a tubular endovascuiar graft may be used to anchor a tubular endovascuiar graft within a blood vessel such that the graft forms an internal conduit through an aneurysm or site of traumatic injury to the blood vessel wall.
  • stents of the prior art have been formed of individual member(s) such as wire, plastic, metal strips, or mesh that have been bent, woven, interlaced or otherwise fabricated into a generally cylindrical configuration. These stents of the prior art have generally been classified into two major categories: a) "self-expanding" stents, and b) "pressure expandable” stents. Some examples of stents of the prior art include those described in United States Patent Nos. 5,405,377 (Cragg); 5,882,335 (Leone, et al.; 6,017,362 (Lau); 6,066,168 (Lau); 6,086,604 (Fischell et al.) and 6,117,165 (Becker).
  • Self-expanding stents are typically formed of spring metal, shape memory alloy, or other material that is resiliently biased toward its fully radially expanded configuration or is otherwise capable of self-expanding to its fully radially expanded configuration without need for the exertion of outwardly directed radial force upon the stent by an extraneous expansion apparatus (e.g., a balloon or mechanical expander tool).
  • Such self- expanding stents may be initially radially compressed and loaded into a small diameter delivery catheter or alternatively mounted upon the outer surface of a delivery catheter equipped with a means for restraining or maintaining the stent in its radially compressed state.
  • the delivery catheter is inserted into the body and is advanced to a position wherein the stent is located at or near the site at which it is to be implanted. Thereafter, the stent is expelled from the delivery catheter and allowed to self-expand to its full radial diameter. Expansion of the stent causes the stent to frictionally engage the surrounding wall of the body cavity or passageway in which it has been positioned. The delivery catheter is then extracted, leaving the self-expanded stent at its intended site of implantation.
  • Pressure-expandable stents of the prior art are typically formed of metal wire, metal strips, or other malleable or plastically deformable material, fabricated into a generally cylindrical configuration.
  • the pressure-expandable stent is initially disposed in a collapsed configuration having a diameter that is smaller than the desired final diameter of the stent when implanted in the blood vessel.
  • the collapsed stent is first loaded into or mounted upon a small diameter delivery catheter.
  • the delivery catheter is then advanced to its desired location within the vasculature, and a balloon or other stent-expansion apparatus (which may be formed integrally of or incorporated into the delivery catheter) is utilized to exert outward radial force on the stent, thereby radially expanding and plastically deforming the stent to its intended operative diameter whereby the stent frictionally engages the surrounding blood vessel wall.
  • the material of the stent undergoes plastic deformation during the pressure- expansion process. Such plastic deformation of the stent material causes the stent to remain in its radially expanded operative configuration.
  • the balloon or other expansion apparatus is then deflated/collapsed and is withdrawn from the body separately from, or as part of, the delivery catheter, leaving the pressure-expanded stent at its intended site of implantation.
  • pressure-expandable stents of the prior art include those described in United States Patent Nos. 5,135,536 (Hillstead); 5,161 ,547 (Tower); 5,292,331 (Boneau); 5,304,200 (Spaulding) and 4,733,665 (Palmaz). iv. Drug eluting stents
  • a continuing need in the stented graft art is for a stented graft capable of providing drug therapy after implantation.
  • the specific drug needed by patients who are being treated by the implantation of stented grafts varies with the type of pathology being treated — for example, whether cardiovascular, hepatic, or gastrointestinal.
  • cardiovascular pathologies it is pertinent that restenosis is observed in up to 50% of patients involved in angioplasty procedures. Restenosis refers to the reclosure of vessels by cellular or other invasion following vessel-clearing procedures.
  • Restenosis is actually a natural healing process involving elements of the clotting cascade and later uncontrolled migration and proliferation of smooth muscle cells (SMC).
  • SMC smooth muscle cells
  • the ultimate result is stenosis of the vessel — a return to the condition for which the treatment was initiated.
  • Such cellular invasion is also a major problem in hepatic stenting procedures.
  • Pertinent therapeutic substances include antiplatelet agents, anticoagulant agents, antimetabolic agents, vasoactive agents such as nitric oxide releasing agents, anti-inflammatory, antiproliferative, pro-endothelial, antisense and anti-migratory agents, all of which are embodied in the present invention.
  • antiplatelet agents include antiplatelet agents, anticoagulant agents, antimetabolic agents, vasoactive agents such as nitric oxide releasing agents, anti-inflammatory, antiproliferative, pro-endothelial, antisense and anti-migratory agents, all of which are embodied in the present invention.
  • antiplatelet agents include antiplatelet agents, anticoagulant agents, antimetabolic agents, vasoactive agents such as nitric oxide releasing agents, anti-inflammatory, antiproliferative, pro-endothelial, antisense and anti-migratory agents, all of which are embodied in the present invention.
  • antimicrobial agents to counter the possibility of infection is therefore of major interest
  • sirolimus also known as rapamycin, an immunosuppressive and antiproliferative compound.
  • Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus and has the molecular weight 914.2.
  • Paclitaxel is a natural product that blocks vital mitotic cellular functions, and hence cellular proliferation. Paclitaxel has a molecular weight of 853.9.
  • researchers at three German hospitals covered stents with low doses of paclitaxel designed to elute the drug for 28 days.
  • no patient using a paclitaxel treated stent exhibited restenosis, whereas 11 % of control patients exhibited restenosis.
  • One problem that has been associated with certain drug eluting stents is the development of an "edge effect" at the edges of the stents after placement.
  • the "edge effect” comprises such phenomena as lumen reduction, neointimal proliferation inside the stented segment, plaque proliferation, and remodeling at the proximal and distal edges of the stent.
  • This invention generally embraces drug eluting stented grafts wherein the drug eluting capability is provided by a composite of drug material and a bioerodible polymer.
  • a feature of the invention is the discovery of a particularly useful group of bioerodible polymers for this purpose. These polymers are fully described In U.S. Patent 4,131 ,648 by Nam S. Choi and Jorge Heller, issued December 26, 1978, assigned to Alza Corporation, and entitled “Structured Orthoester and Orthocarbonate Drug Delivery Devices", which is incorporated herein in its entirety by reference.
  • the patent discloses a class of polymers comprising a polymeric backbone having a repeating unit comprising hydrocarbon radicals and a symmetrical dioxycarbon unit with a multiplicity of organic groups bonded thereto.
  • the polymers prepared by the invention have a controlled degree of hydrophobicity with a corresponding controlled degree of erosion in an aqueous or like environment to innocuous products.
  • the polymers can be fabricated into coatings for releasing a beneficial agent, as the polymers erode at a controlled rate, and thus can be used as carriers for drugs for releasing drug at a controlled rate to a drug receptor, especially where bioerosion is desired.
  • VBT intravascular brachytherapy
  • a stent a further approach to reduce restenosis after percutaneous coronary intervention
  • VBT intravascular brachytherapy
  • Radiation sources for this purpose include palladium-103 ( 103 Pd), a low energy photon emitter.
  • Other brachytherapy sources include 192 lr, 32 P, and 188 Re. Sr/Y90 source trains have also been employed.
  • the present invention provides a solution to the long-standing need for a stent for VBT.
  • SFV Semliki Forest Virus
  • Elastomers including fluoropolymers such as polytetrafluoroethylene, have been heretofore used for the manufacture of various types of prosthetic vascular grafts. These vascular grafts are typically of tubular configuration so as to be useable to replace an excised segment of blood vessel.
  • tubular elastomer vascular grafts of the prior art have traditionally been implanted, by open surgical techniques, whereby a diseased or damaged segment of blood vessel is surgically excised and removed, and the tubular bioprosthetic graft is then anastomosed into the host blood vessel as a replacement for the previously removed segment thereof.
  • tubular prosthetic vascular grafts have also been used as bypass grafts wherein opposite ends of the graft are sutured to a host blood vessel so as to form a bypass conduit around a diseased, injured or occluded segment of the host vessel.
  • tubular prosthetic vascular grafts of the prior art have been formed of extruded, porous PTFE tubes.
  • a PTFE tape is wrapped about and laminated to the outer surface of a tubular base graft to provide reinforcement and additional burst strength.
  • some of the prior tubular prosthetic vascular grafts have included external support member(s), such as a PTFE beading, bonded or laminated to the outer surface of the tubular graft to prevent the graft from becoming compressed or kinked during implantation.
  • tubular vascular grafts have proven to be particularly useful for replacing segments of blood vessel which pass through, or over, joints or other regions of the body which undergo frequent articulation or movement.
  • One commercially available, externally-supported, tubular vascular graft is formed of a PTFE tube having a PTFE filament helically wrapped around, and bonded to, the outer surface of the PTFE tube. (IMPRA FlexTM Graft, IMPRA, Inc., Tempe, AZ)
  • One other commercially available, externally-supported, tubular vascular graft comprises a regular walled, PTFE tube which has PTFE reinforcement tape helically wrapped around, and bonded to, the outer surface of the PTFE tube and individual rings of Fluorinated Ethylene Propylene (FEP) rings disposed around, and bonded to, the outer surface of the reinforcement tape.
  • FEP Fluorinated Ethylene Propylene
  • stented grafts typically comprise a self-expanding or pressure-expandable stent that is affixed to or formed within a pliable tubular graft. Because of their radial compressibility/expandability, these stented grafts are particularly useable in applications wherein it is desired to insert the graft into an anatomical passageway (e.g., blood vessel) while the graft is in a radially compact state, and to subsequently expand and anchor the graft to the surrounding wall of the anatomical passageway.
  • anatomical passageway e.g., blood vessel
  • tubular prosthetic vascular grafts within the lumen of a blood vessel, by percutaneous or minimal incision means.
  • endovascuiar implantation initially involves transluminal delivery of the graft, in a compacted state, by way of a catheter or other transluminally advancable delivery apparatus. Thereafter, the graft is radially expanded and anchored to the surrounding blood vessel wall, thereby holding the graft at its intended site of implantation within the host blood vessel.
  • An affixation apparatus such as a stent may be utilized to anchor at least the opposite ends of the tubular graft to the surrounding blood vessel wall.
  • endovascuiar grafts of this type are in the treatment of vascular aneurysms without requiring open surgical access and resection of the aneurysmic blood vessel.
  • stented grafts may also be useable to treat occlusive vascular disease-especially in cases where the stented graft is constructed in such a manner that the tubular graft material forms a complete barrier between the stent and the blood that is flowing through the blood vessel.
  • tubular graft material may serve as a smooth, biologically compatible, inner "covering" for the stent, thereby preventing a) turbulent blood-flow as the blood flows over the wire members or other structural material of which the stent is formed, b) immunologic reaction to the metal or other material of which the stent is formed, and c) a barrier to separate a diseased or damaged segment of blood vessel from the blood-flow passing therethrough.
  • Such prevention of turbulent blood-flow and/or immunologic reaction to the stent material is believed to be desirable as both of these phenomena are believed to be associated with thrombus formation and/or restenosis of the blood vessel.
  • Other uses for stented grafts may include restoring patency to, or re- canalizing, other anatomical passageways such as ducts of the biliary tract, digestive tract and/or genitourinary tract.
  • a number of specific desiderata are of special importance with regard to the suitability of particular expandable stent designs for incorporation into a drug eluting stented graft.
  • these are high flexibility, high hoop strength of the stent in its expanded form, minimal foreshortening of the stent in the course of its transition from a compressed state to an expanded state, and minimal "dog bone effect.”
  • High flexibility is necessary in order for the drug eluting stented graft to be smoothly inserted into regions of convolution.
  • High hoop strength is necessary in order that the stent will fulfill its primary function of holding a lumen open.
  • the present invention is directed to improved tubular drug eluting stented grafts and their methods of manufacture.
  • the present invention may exist in numerous embodiments, including those wherein the stent component of the graft is formed integrally within the tubular graft or wherein it is situated on the inner surface of the tubular graft.
  • Embodiments of the invention may be self-expanding, incorporating a self- expanding stent, or pressure-expandable, incorporating a pressure- expandable stent.
  • an improved integrally drug eluting stented elastomer graft which comprises a tubular base graft, a radially expandable stent surrounding the outer surface of the tubular base graft, and an outer elastomer layer.
  • the tubular outer layer is fused to the tubular base graft through lateral openings or perforations formed in the stent.
  • a drug delivery coating is disposed on the stent.
  • an improved internally drug eluting stented, tubular elastomer graft which comprises a radially compressible/expandable stent having a elastomer tube coaxially disposed outside of the stent, with the inner surface of the tubular elastomer graft being fused or attached to the stent.
  • a drug delivery coating is applied to or formed on the stent.
  • the invention may be manufactured by a method which comprises the steps of: a) initially positioning a generally cylindrical stent of either the self-expanding or pressure-expandable variety in contacting coaxial relation with the tubular base graft and/or the tubular outer layer, upon a cylindrical mandrel or other suitable support surface, and b) subsequently fusing (i.e., heating to a lamination temperature) the assembled components (i.e., the stent in combination with the inner base graft and/or outer tubular layer) of the drug eluting stented graft into a unitary drug eluting stented graft structure.
  • Heating is accomplished using a "waffle- iron” heater wherein heat is applied only to areas that correspond to the spaces not occupied by the stent.
  • the purpose of the "waffle-iron” heater is to avoid heating the drug covering the stent to its decomposition temperature. Such heating will cause the outer layer to heat fuse to the inner base graft through the openings that exist in the stent.
  • An alternative to the "waffle-iron” heater is to use a laser beam controlled by a computer to "hit" only the areas corresponding to the openings that exist in the stent. Computer controlled laser beams to accomplish such a purpose are known in the art.
  • the drug eluting stented elastomer grafts of the present invention are capable of radially expanding and contracting without excessive puckering, wrinkling or invagination of the graft material.
  • the manufacturing methods and materials of the present invention render the elastomer sufficiently strong and sufficiently firmly laminated or fused so as to permit such relative movement of the individual members of the stent without tearing or rupturing of the tubular graft.
  • Figure 1 is a perspective view of a drug eluting radially expandable tubular stented graft of the present invention, wherein a portion of the graft has been inserted into a tubular catheter.
  • Figure 1a is an enlarged perspective view of a segment of Figure 1.
  • Figure 2 is an enlarged, cut-away, elevational view of a drug eluting radially expandable tubular stented graft of the present invention.
  • Figure 3a is an enlarged perspective view of a portion of the drug eluting radially expandable stent of the present invention incorporated in the graft of Figure 2.
  • Figure 3b is an enlarged cross-sectional view through line 3b-3d of Figure 3a.
  • Figures 4a-4f are a step-by-step illustration of a preferred method for manufacturing a drug eluting radially expandable tubular stented graft of the present invention.
  • Figure 5 is a schematic illustration of an alternative electron beam deposition method which is usable for depositing a coat comprising a composite of at least one polymer and at least one therapeutic substance on the drug eluting radially expandable stent of the present invention.
  • Figure 6 is a schematic diagram of a "waffle iron" heating apparatus which is useable in the manufacture of a drug eluting radially expandable stent of the present invention.
  • Figure 7 is a perspective view of a section of a drug eluting radially expandable stent of the present invention that illustrates portions of three elements each comprising an undulating zigzag shape.
  • Figure 7a is an enlarged longitudinal sectional view of a drug eluting radially expandable stent of the invention shown in Fig. 7 taken along section line 7a therein.
  • Figure 8 is a perspective view of a section of a drug eluting radially expandable stent of the invention that illustrates portions of two elements each comprising an undulating sinusoidal shape.
  • Figure 8a is an enlarged longitudinal sectional view of a drug eluting radially expandable stent of the invention shown in Fig. 8 taken along section line 8a therein.
  • Figure 9 is an enlarged, cut-away, elevational view of a drug eluting radially expandable tubular stented graft of the present invention.
  • the drug delivery polymers in the drug delivery stents of the invention can be used as a single film or in a number of layers made of the same or of different polymers. They have a controlled degree of hydrophobicity in the environment of use and they erode into innocuous products at a continuous rate which exhibits no known deleterious effects on the environment or towards an animal body.
  • hydrophilcity as used above and in the remainder of the specification broadly refers to the property of the polymers not to absorb appreciable amounts of water.
  • electrodedible and
  • bioerodible as used herein define the property of the polymers to break down as a unit structure or entity in a non-biological or in a biological environment over a period of time to innocuous products.
  • the terms “erosion”, “bioerode” and “bioerosion” generally define the method and environment where breakdown or degradation of the polymer occurs.
  • the phrase “prolonged period of time” as used herein, generally means the period between the start of erosion or the breakdown of the polymers when the polymers are placed in a moisture laden environment and that period in time when the polymer is gone.
  • the period may continue over days, several months such as ninety days, one hundred and eighty days, a year or longer.
  • the environment includes aqueous and aqueous-like biological environments.
  • therapeutic agent as used in the specification and accompanying claims includes any compound, mixture of compounds, or composition of matter consisting of a compound and a carrier, which when released from a stented graft produces a beneficial and useful result.
  • the drugs that may be administered include inorganic and organic drugs without limitation.
  • the agents or drugs also can be in various forms, such as uncharged molecules, components of molecular complexes, pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulfate, laurate, palmitate, phosphate, nitrate, borate, acetate, maleate, tartrate, oleate, and salicylate.
  • pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulfate, laurate, palmitate, phosphate, nitrate, borate, acetate, maleate, tartrate, oleate, and salicylate.
  • salts of metals, amines, or organic cations for example quaternary ammonium can be employed.
  • simple derivatives of drugs such as esters, ethers, and amides that have solubility characteristics that are suitable for the purpose of the invention can be employed.
  • an agent or drug that is water insoluble can be used in a form that is a water soluble derivative thereof to effectively serve as a solute, and on its release from the device, is converted by enzymes, hydrolyzed by body pH, or metabolic processes to the original form or to a biologically active form.
  • agents or drug formulations within the devices can have various art known forms such as solutions, dispersions, pastes, particles, granules, emulsions, suspensions and powders.
  • the drug eluting stented grafts of the present invention Utilize bioerodible, agent-release, rate controlling materials that bioerode at a controlled and continuous rate concurrently with the release of agent at a corresponding controlled and continuous rate.
  • Devices made with the present bioerodible polymers are reliable and easy to use for releasing an agent as they normally require intervention or handling only at the time when the device is positioned in the patient.
  • the devices can be made to release an agent at a zero rate or at a variable rate by controlling the molecular weight and composition of the polymer, by controlling the concentration of the agent in the polymer and the surface area exposed, and by making the devices with different drug delivery polymers that undergo bioerosion and agent release at different rates, or by fabricating the polymer coated stents integrally into stented grafts wherein the graft polymer controls drug release.
  • the polymers comprising a carbon-oxygen backbone having a dioxycarbon moiety with a plurality of organic groups pendant from the dioxycarbon.
  • the bioerodible polymers are represented by the following general formula:
  • WHEREIN Ri is a di, tri or tetravalent alkylene, alkenylene, alkyleneoxy, cycloalkylene, cycloalkylene substituted with an alkyl, alkoxy or alkenyl, cycloalkenylene, cycloalkenylene substituted with an alkyl, alkoxy or alkenyl, arylene, or a arylene substituted with an alkyl, alkoxy or alkenyl, R 2 and R 3 are alkyl, alkenyl, alkoxy, alkenyloxy, alkylene, alkenylene, alkyleneoxy, alkenyleneoxy, alkylenedioxy, alkenylenedioxy, aryloxy, aralkyleneoxy, aralkenyleneoxy, aralkylenedioxy, aralkenylenedioxy, oxa, or OR 1 O with Ri defined as above; and wherein, (a) Ri is divalent when R 2 and R 3 are alky
  • the polymers include homopolymers, copolymers of the random and block types formed by reacting monomers or mixtures of preformed homopolymers and/or copolymers, branched polymers and cross-linked polymers.
  • Thermoplastic linear polymers are afforded when Ri is divalent, R 2 and R 3 are substituted with a noncross-linking group or are bonded intramolecularly; thermosetting cross-linked polymers are produced when Ri is divalent and R 2 and R 3 is intermolecularly bonded between different polymeric backbones; and, thermosetting cross-linked polymers result when Ri is tri or tetravalent and R 2 and R 3 are substituted with noncross- linking groups, or bonded intramolecularly.
  • a typical drug eluting radially expandable tubular stented graft having a stent coated with a polymer having an erosion rate of about 2 ⁇ per hour in a biological aqueous environment with a physiological pH of 6 to 8 and a drug concentration of 5% can be prepared as follows: To 2.375 g of poly(2,2-dioxo-trans-1 ,4-cyclohexane dimethylene tetrahydrofuran) was added 0.125 g of hydrocortisone and the ingredients heated to 150° C. to give a melt. The drug was dispersed throughout the melt by mixing the ingredients for 5 minutes to give a good dispersion. The mixing was performed in a dry, inert environment, at atmospheric pressure, and with dry equipment.
  • a stent was dipped into the molten polymer and withdrawn in order to coat the stent. After cooling, the stent was fabricated into a stented graft. The graft, was placed in a biological aqueous environment where the coat bioeroded and released steroid for the potential management of inflammation.
  • Graft 10 comprises a tubular base graft 12, a stent 14 coated with a coat comprising a composite of at least one polymer and at least one therapeutic substance, and an outer layer of elastomer 16.
  • Stent 14 is formed of metal, such as an alloy of cobalt, chromium, nickel or molybdenum, wherein the alloying residue is iron.
  • Stent 14 may be radially compressed to a smaller diameter Di and radial constraint, as may be applied by the surrounding wall of the tubular delivery catheter 22 shown in Figure 1 , may be applied to hold the stent 14 in such radially compressed state (diameter Di). Thereafter, when the radial constraint is removed from the stent 14, the stent 14 will resiliently spring back to its radially expanded diameter D 2 .
  • Stent 14 may be a shape memory alloy that can alternately exist in a first and a second crystalline state, or it may be a pressure- expandable stent.
  • Stent 14 may be formed of a metal alloy comprising at least two elements selected from the group consisting of iron, cobalt, chromium, nickel, titanium, niobium, and molybdenum.
  • the alloy may comprise at least about 51 % to about 59% nickel and the remainder comprising titanium.
  • it may comprise about 0.25% chromium, at least about 51 % to about 59% nickel, and the remainder comprising titanium.
  • tubular base graft 12 begins with the step of preparing a PTFE paste dispersion for subsequent extrusion.
  • This PTFE paste dispersion may be prepared by known methodology whereby a fine, virgin PTFE powder (e.g., F-104 or F-103 Virgin PTFE Fine Powder, Dakin America, 20 Olympic Drive, Orangebury, NY 10962) is blended with a liquid lubricant, such as odorless mineral spirits (e.g., Isopar®, Exxon Chemical Company, Houston, TX 77253-3272), to form a PTFE paste of the desired consistency.
  • a fine, virgin PTFE powder e.g., F-104 or F-103 Virgin PTFE Fine Powder, Dakin America, 20 Olympic Drive, Orangebury, NY 10962
  • a liquid lubricant such as odorless mineral spirits (e.g., Isopar®, Exxon Chemical Company, Houston, TX 77253-3272), to form a PTFE paste of the desired consistency
  • the PTFE-lubricant blend dispersion is subsequently passed through a tubular extrusion dye to form a tubular extrudate. iii.) Drying
  • the wet tubular extrudate is then subjected to a drying step whereby the liquid lubricant is removed.
  • This drying step may be accomplished at room temperature or by placing the wet tubular extrudate in an oven maintained at an elevated temperature at or near the lubricant's dry point for a sufficient period of time to result in evaporation of substantially all of the liquid lubricant, iv.) Expansion
  • the dried tubular extrudate is longitudinally expanded or longitudinally drawn at a temperature less than 327°C and typically in the range of 250-326°C.
  • This longitudinal expansion of the extrudate may be accomplished through the use of known methodology, and may be implemented by the use of a batch expander.
  • the tubular extrudate is longitudinally expanded by an expansion ratio of more than two to one (2:1 ) (i.e., at least two (2) times its original length), v.) Sintering
  • the expanded PTFE tube is subjected to a sintering step whereby it is heated to a temperature above the sintering temperature of PTFE (i.e., 350- 370°C) to effect amorphous-locking of the PTFE polymer.
  • a sintering step whereby it is heated to a temperature above the sintering temperature of PTFE (i.e., 350- 370°C) to effect amorphous-locking of the PTFE polymer.
  • the methodology used to effect the sintering step, and the devices used to implement such methodology, are known in the art.
  • the PTFE tape 16 may be manufactured by any suitable method, including the general method for manufacturing expanded PTFE tape.
  • stent 14 Prior to assembly of the components of graft 10, stent 14 is coated with a coating 20 comprising a composite of at least one polymer and at least one therapeutic substance.
  • a coating 20 comprising a composite of at least one polymer and at least one therapeutic substance.
  • it may be coated with a polymer having an erosion rate of about 2 ⁇ per hour in a biological aqueous environment with a physiological pH of 6 to 8 and a drug concentration of 5% prepared as follows: To 2.375 g of poly(2,2-dioxo- trans-1 ,4-cyclohexane dimethylene tetrahydrofuran) was added 0.125 g of hydrocortisone and the ingredients heated to 150° C. to give a melt. The drug was dispersed throughout the melt by mixing the ingredients for 5 minutes to give a good dispersion.
  • stent 14 may be immersed in a vessel 30 into the molten polymer 32 and withdrawn in order to coat the stent.
  • the time in which stent 14 must remain immersed in liquid 32 varies depending on the construction of stent 14 and the chemical composition of liquid 32. However, in most cases, an immersion time of 10-15 seconds will be sufficient to obtain uniform deposition of the coating 20 on the wire members 18 of stent 14 (Fig. 3b).
  • stent 14 After stent 14 has been removed from liquid 32, it will be permitted to air dry such that a dry coating 20 remains deposited upon the outer surface of each wire 18 of stent 14.
  • coated stent 14 may be subjected to electron beam deposition, as illustrated in Figure 5, to enhance the bonding of coating 20 to wire members 18 of stent 14.
  • stent 14 is positioned within a closed vacuum chamber 36 wherein a mass comprising a composite of at least one polymer and at least one therapeutic substance 38 is located.
  • An electron beam apparatus 40 is then utilized to project electron beam radiation onto mass 38 within the chamber 36 so as to cause sublimation of mass 38 and resultant deposition of layer 20 on the outer surface of stent 14.
  • the apparatus and specific methodology useable to perform this electron beam deposition of coating 20 are well known to those of skill in the relevant art. D. Assembly and Construction of the Integrally Drug eluting stented PTFE Graft
  • Figures 4b-4f show, in step-wise fashion, the preferred method for assembling and constructing graft 10.
  • tubular base graft 12 is initially disposed on a rod or mandrel 50.
  • Mandrel 50 may comprise a stainless steel rod having an outer diameter that is only slightly smaller than the inner diameter of graft 12.
  • graft 12 may be slidably advanced onto the outer surface of mandrel 50 without undue effort or damage.
  • coated stent 14 is axially advanced onto the outer surface of graft 12, as shown in Figure 4c.
  • PTFE tape 17 is helically wrapped in a first direction in overlapping fashion on the outer surface of stent 14.
  • tape of V. inch width is used.
  • the tape is helically wrapped about the stent at a pitch angle whereby 6 to 8 revolutions of the tape are applied per linear inch of stent 14.
  • a second tape wrap in the opposite direction is accomplished, preferably using the same width of tape at the same pitch angle, thereby applying another 6-8 revolutions of tape 17 per linear inch of stent 14. In this manner, both wrappings of tape 17 (Figs.
  • a tubular, outer PTFE layer 16 which preferably has a thickness of less than 0.1 inches, and which may be formed of 1 to 10 consecutive (e.g., laminated) layers of the tape 17.
  • the first helical wrap may deposit four consecutive layers of tape 17
  • the second helical wrap may deposit an additional 4 layers of tape 17, thereby resulting in an outer tubular layer 16 which is made up of a total of 8 layers of tape 17.
  • liquid PTFE dispersion may be sprayed, painted or otherwise applied to and dried upon tape 17 prior to wrapping, or such liquid PTFE dispersion may be deposited by any suitable means (spraying, painting, etc.) between the outer tubular layer 16 formed by helically wrapped tape 17 and inner base graft 12.
  • liquid PTFE dispersion may be sprayed onto or otherwise applied to the outer surface of helically wrapped tape 17 such the small particles of PTFE contained within the liquid dispersion will migrate inwardly through pores in the layers of tape 17, and will thereby become deposited between outer tubular layer 16 and inner base graft 12 prior to subsequent heating of the assembly, as described below.
  • ligatures 52 of stainless steel wire are tied about the opposite ends of graft 10 so as to securely hold base graft 12, coated stent 14 and outer layer 16 on the mandrel 50.
  • the mandrel having graft 10 disposed thereon is then heated using a "waffle- iron" heater, schematically shown in Fig. 4f, wherein heat is applied only to areas that correspond to the spaces not occupied by stent 14.
  • the purpose of the "waffle-iron” heater is to avoid heating the drug covering the stent to its decomposition temperature. Heating causes outer PTFE layer 16 to heat fuse to inner base graft 12 through the openings 19 which exist in stent 14.
  • inner base graft 12 is eliminated, thereby providing a drug eluting stented graft 10 comprising only stent 14 and outer tubular layer 16.
  • This embodiment is of particular utility in connection with reducing the tendency of tissue ingrowth into the stent in certain applications.
  • therapeutic agents including, sirolimus, paclitaxel, brachytherapeutic agents, and the like may be incorporated into the stent as taught by the invention to avoid such ingrowth.
  • These stents are of particular importance as trans-hepatic stents, where such ingrowth is an important problem.
  • the above-described manufacturing method is performed as described without tubular base graft 12, thereby forming a modified version of drug eluting stented graft 10 wherein outer tubular layer 16 is fused only to stent 14.
  • stent 14 is coated with a lubricious polymer coating to provide lubricity and biocompatibility, which renders the graft suitable for use in applications wherein the exposed stent 14 will come in direct contact with biological fluid or blood.
  • this embodiment of the present invention includes all possible arrangements wherein only outer tubular layer 16 is utilized in conjunction with stent 14, to provide an internally drug eluting stented graft 10 which is devoid of any internal tubular base graft 12.
  • Fig. 7 and Fig. 8 there are shown portions of two embodiments of the stent of the invention.
  • Stent portion 100 consists of three elements 101 , 102 and 103, each of which comprises a zigzag pattern comprising a plurality of zigs having tips and a plurality of zags having tips.
  • a tip 104 on a zig of element 101 and a nearest tip 105 of a zag of an adjacent neighbor element 105 generally lie in a plane passing through the cylinder axis, and are connected by a linear connector 105.
  • a tip 106 on a zig of element 102 and a nearest tip 107 on a zag of an adjacent neighbor element 103 generally lie in a plane passing through the cylinder axis, and are connected by a linear connector 111.
  • Connector 111 is substantially circumferentially offset from adjacent neighbor connector 105.
  • Stent 100 is constructed of material that has a width dimension 140 and a depth dimension 150 each of which is smaller than the length dimension of linear connectors 1 10 and 11 1.
  • Stent portion 200 consists of two elements 201 and 202, each of which comprises an undulating pattern comprising a plurality of peaks and valleys.
  • a valley 220 on element 201 and a nearest peak 230 of adjacent neighbor element 202 generally lie in a plane passing through the cylinder axis, and are connected by a linear connector 210.
  • Stent 200 is constructed of material that has a width dimension 240 and a depth dimension 250 each of which is smaller than the length dimension of connector 210.
  • the wire and gap features of the older stent art shown at 330 and 340 are combined elements having zigzag features, shown at 310, and sinusoidal features, shown at 300. All elements of the 310 and 300 type are connected using connectors as shown at 320.
  • the resulting stent may be fabricated into any of the embodiments of the present invention.
  • the invention comprises an improved stented graft that can alternately include a compact configuration having a first diameter and an expanded configuration having a greater diameter, comprising, in combination at least one stent formed in a generally cylindrical shape having an outer surface and a hollow bore extending longitudinally therethrough, wherein the stent can alternately exist in a compact configuration having a first diameter, and an expanded configuration having a greater diameter and a plurality of lateral openings; and, a flexible, porous, biocompatible tubular elastomer covering having a first end, a second end, an outer surface and a hollow bore that extends longitudinally therethrough to define an inner surface.
  • the stent is deployed coaxially within the hollow bore of the covering such that the inner surface of the tubular covering is in contact with the outer surface of the stent.
  • FIG. 1 Another embodiment is a tubular stented graft that is alternately deployable in a radially compact configuration having a first diameter and a radially expanded configuration having a second diameter.
  • This stented graft includes a stent comprising at least one member formed in a generally cylindrical shape having an outer surface and a hollow bore which extends longitudinally therethrough to define an inner surface.
  • the stent is initially radially collapsible to a diameter that is substantially equal to the first diameter of the stented graft, and subsequently radially expandable to a diameter which is substantially equal to the second diameter of the stented graft.
  • a plurality of lateral openings exists in the stent when the stent is at its radially expanded second diameter.
  • a continuous, tubular PTFE covering is formed on the stent, the PTFE covering comprising a tubular inner base graft formed of expanded, sintered PTFE.
  • the tubular base graft has an outer surface and an inner surface, the tubular base graft being deployed coaxially within the hollow bore of the stent such that the outer surface of the tubular base graft is in contact with the inner surface of the stent, and the inner surface of the tubular base graft thereby defining a luminal passageway through the stented graft.
  • a tubular outer layer is formed of expanded, sintered PTFE tape which has a width of less than about 1 inch, the tape having been wound about the outer surface of the stent to create the tubular outer layer thereon, such that the stent is captured between the outer layer and the tubular base graft.
  • the tubular outer layer is attached to the tubular base graft through the lateral openings in the stent to form an integrally stented, continuous PTFE tube which is alternately disposable in the radially compact configuration of the first diameter and the radially expanded configuration of the second diameter.
  • the improvement comprises the device wherein the stent is coated with a coat comprising a composite of at least one biocompatible, pharmaceutically acceptable, bioerodible polymer and at least one therapeutic substance to form a drug eluting stented graft.
  • the polymer may be a polyester.
  • the therapeutic agent may be selected from the group consisting of antiplatelet agents, anticoagulant agents, antimetabolic agents, vasoactive agents, nitric oxide releasing agents, anti-inflammatory agents, antiproliferative agents, antisense agents, pro- endothelial agents, anti-migratory agents, antimicrobial agents, selective gene delivery vectors, sirolimus, actinomycin-D and paclitaxel.
  • the selective gene delivery vectors may include Semliki Forest Virus (SMV) adapted to deliver restenosis preventing genes.
  • SMV Semliki Forest Virus
  • the polymer may be a hydrophobic, bioerodible, copolymer comprising mers I and II according to the following formula wherein:
  • ⁇ i is a member selected from the group consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; alkyleneoxy of
  • the at least one polymer may be a hydrophobic, bioerodible, terpolymer comprising mers I, II, and III according to the following formula, wherein:
  • Ri is a member selected from the group consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; alkyleneoxy of 2 to 6 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with a member selected from the group consisting of alkyl of 1 to 7 carbons, alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; cycloalkenylene of 4 to 7 carbons; cycloalkenylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; arylene; and arylene substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, an alkenyl of 2 to
  • the composite of at least one polymer and at least one therapeutic substance when in operation bioerodes and releases the at least one therapeutic substance at a rate selected from (1 ) a zero order rate, (2) a continuous rate, and (3) a variable rate, which rate is produced by preselecting the composite of the at least one polymer and the at least one therapeutic substance, and the elastomer to give the desired result.
  • the drug eluting stented graft may include a multiplicity of microcapsules dispersed within the at least one polymer.
  • the microcapsules have a wall formed of a drug release rate controlling material and therapeutic substance is contained within the multiplicity of microcapsules.
  • the at least one polymer may have the formula:
  • Ri is a member selected from the group of divalent, trivalent and tetravalent radicals consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; alkyleneoxy of 2 to 6 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with an alkyl of 1 to 7 carbons, alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; cycloalkenylene of 4 to 7 carbons cycloalkenylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; arylene; and arylene substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, and an alkenyl of 2 to 7 carbons; R
  • the polymer and the microcapsules bioerode at a controlled and continuous rate over a prolonged period of time, thereby releasing the at least one therapeutic substance at a controlled and continuous rate over a prolonged period of time.
  • the coat of the stent of the drug eluting stented graft may further comprise at least a first layer and a second layer, wherein the first layer comprises the at least one therapeutic substance and at least a first polymer, and the second layer comprises the at least one therapeutic substance and at least a second polymer. At least one of the first polymer and the second polymer are selected from the group consisting of polymers of the formula:
  • R ⁇ is a member selected from the group of divalent, trivalent and tetravalent radicals consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; alkyleneoxy of 2 to 6 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with an alkyl of 1 to 7 carbons, alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; cycloalkenylene of 4 to 7 carbons; cycloalkenylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; arylene; and arylene substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, and an alkenyl of 2 to 7 carbons;
  • the first polymer may be a pharmaceutically acceptable biocompatible non-bioerodible polymer that sequesters an agent, such as palladium-103 ( 103 Pd), 192 lr, 32 P, 188 Re, and Sr/Y90 source trains, for brachytherapy.
  • an agent such as palladium-103 ( 103 Pd), 192 lr, 32 P, 188 Re, and Sr/Y90 source trains, for brachytherapy.
  • the drug eluting stented graft may have a multiplicity of discrete, closed cells within the at least one polymer, the cells having a wall formed and defined by the at least one polymer.
  • the polymer has the formula:
  • Ri is a member selected from the group of divalent, trivalent and tetravalent radicals consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; alkyleneoxy of 2 to 6 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with an alkyl of 1 to 7 carbons, alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; cycloalkenylene of 4 to 7 carbons; cycloalkenylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; arylene; and arylene substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, and an alkenyl of 2 to 7 carbons;
  • the at least one therapeutic substance is dissolved in a pharmaceutically acceptable carrier that is a solvent for the at least one therapeutic substance and a nonsolvent for the at least one polymer is contained within the multiplicity of discrete, closed cells.
  • a pharmaceutically acceptable carrier that is a solvent for the at least one therapeutic substance and a nonsolvent for the at least one polymer is contained within the multiplicity of discrete, closed cells.
  • the at least one polymer is capable of bioeroding at a controlled and continuous rate over a prolonged period of time, thereby releasing the at least one therapeutic substance at a controlled and continuous rate over a prolonged period of time.
  • the stent comprises a plurality of elements. Each element comprises an undulating linear shape formed into a generally cylindrical configuration having a cylinder axis generally aligned on the axis of the hollow bore, and each element is connected to an adjacent neighbor element by at least one linear connector.
  • the elements may comprise a spiral.
  • One connector may be substantially circumferentially offset from an adjacent neighbor connector, and may form a helical array. Alternatively, a connector may not be substantially circumferentially offset from an adjacent neighbor connector.
  • the undulating linear shape may be a generally zigzag shape comprising a plurality of zigs having tips and a plurality of zags having tips, wherein the tip of each zig of each element and the nearest the tip of each zig of an adjacent neighbor element generally lie in a plane passing through the axis of the hollow bore, and wherein the tip of at least one zig of each element and at least one nearest tip of a zig of an adjacent neighbor are connected by one linear connector.
  • the undulating linear shape may be a sinusoidal shape having a plurality of peaks and a plurality of valleys.
  • Each peak of each element and each valley of an adjacent neighbor may lie generally in a common plane passing through the axis of the hollow bore, and at least one peak of each element and the valley of an adjacent neighbor lying generally in the common plane may be connected by one linear connector.
  • the length of each linear connector is greater than its width or depth, and may be 3-10 times greater than the width or depth.
  • the stent and elastomer may be anchored to each other by means for anchoring, such as protrusions of the covering that fixedly protrude into the lateral openings in the stent.
  • the elastomer may be polytetrafluoroethylene, fluorinated ethylene propylene, polytetrafluoroethylene-perfluoroalkyl vinyl ether copolymer, polyvinyl chloride, polypropylene, polyethylene terephthalate, broad fluoride, other biocompatible plastics, and expanded, sintered PTFE (which may be tape) having fibrils measuring about 300 ⁇ -5 ⁇ in length.
  • the tape may have a width of less than about 0.5 inches to about 1 inch, a thickness of less than 0.015 inch (0.038 cm.), and a density of less than 1.6 g/cc.
  • the tape may be wound about the stent in overlapping fashion, for example, helically.
  • the tape may be wound in a first direction and then in the opposite direction, and comprise 1 to 10 layers.
  • the tape may be helically wrapped such that 6-8 revolutions of tape are applied per longitudinal inch (2.54 cm.) of the drug eluting stented graft.
  • the thickness of the covering may be less than 0.1 inch (0.25 cm.)
  • the drug eluting stented graft may include a self-expanding stent comprising a shape memory alloy that can alternately exist in a first and a second crystalline state, or it may include a pressure-expandable stent.
  • the stent may be formed of a metal alloy comprising at least two elements selected from the group consisting of iron, cobalt, chromium, nickel, titanium, niobium, and molybdenum.
  • the alloy may comprise at least about 51 % to about 59% nickel and the remainder comprising titanium.
  • it may comprise about 0.25% chromium, at least about 51 % to about 59% nickel, and the remainder comprising titanium.
  • the composite coating of the drug eluting stented graft may be applied to the stent by the steps of immersing the stent in a liquid dispersion of the composite, removing the stent from the liquid dispersion of the composite, and drying the liquid dispersion of the composite that has remained on the stent.
  • the composite coating may be formed by electron beam deposition, and the tubular covering may be adherent to the coat.
  • a method for the treatment of cardiovascular disease comprises implanting the drug eluting stented graft in a patient in need of such treatment wherein the implantation is effective to ameliorate one or more of the symptoms of the cardiovascular disease.
  • An article of manufacture comprises packaging material and the drug eluting stented graft contained within the packaging material, wherein the drug eluting stented graft is effective for implantation in a patient afflicted with cardiovascular disease, and the packaging material includes a label that indicates that the device is effective for said implantation.
  • the linear connectors may collectively form arrays that may be helical, linear, or neither helical nor linear.
  • linear connectors may connect peaks to peaks, valleys to valleys, or peaks to valleys.
  • linear connectors may connect zigs to zigs, zags to zags, or zigs to zags. Accordingly, it is intended that all such reasonable additions, deletions, modifications and alterations to the above described embodiments be included within the scope of the following claims.
  • the product can have other shapes, or could make use of other metals and plastics.
  • the scope of the invention should be determined by the appended claims and their legal equivalents, rather than by the examples given. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Abstract

L'invention porte sur des greffes à stent tubulaire éluant les médicaments, le stent étant recouvert d'un revêtement comprenant un composite constitué d'au moins un polymère bioérodable, acceptable d'un point de vue pharmaceutique, biocompatible et d'au moins une substance thérapeutique. Le polymère peut être un polyester. L'agent thérapeutique peut comprendre des vecteurs d'administration de gènes sélectifs tels que le sirolimus, l'actinomycine D et le paclitaxel. Les greffes à stent tubulaire ont, selon les formes d'exécution, un stent intégré et un stent intérieur, le stent pouvant soit s'autodilater, soit se dilater sous pression. Le stent peut également comprendre une pluralité d'éléments ayant chacun une forme linéaire ondulante créée dans une configuration généralement cylindrique, chaque élément étant raccordé à un élément adjacent par au moins un raccord linéaire. L'invention porte, en outre, sur un procédé de traitement des maladies cardio-vasculaires par implantation de la greffe à stent, et sur un article de fabrication comprenant un matériau de conditionnement et la greffe à stent.
PCT/US2002/035065 2001-10-31 2002-10-31 Greffes a stent tubulaire extensible radialement eluant les medicaments WO2003037397A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2465517A CA2465517C (fr) 2001-10-31 2002-10-31 Greffes a stent tubulaire extensible radialement eluant les medicaments
JP2003539736A JP2005507710A (ja) 2001-10-31 2002-10-31 薬物を溶出する半径方向に拡張可能な管状ステント付き移植片
EP02780558A EP1439868A2 (fr) 2001-10-31 2002-10-31 Greffes a stent tubulaire extensible radialement eluant les medicaments

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US176501A 2001-10-31 2001-10-31
US10/001,765 2001-10-31
US09/997,829 US20020042645A1 (en) 1996-07-03 2001-11-29 Drug eluting radially expandable tubular stented grafts
US09/997,829 2001-11-29

Publications (2)

Publication Number Publication Date
WO2003037397A2 true WO2003037397A2 (fr) 2003-05-08
WO2003037397A3 WO2003037397A3 (fr) 2003-09-18

Family

ID=26669453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035065 WO2003037397A2 (fr) 2001-10-31 2002-10-31 Greffes a stent tubulaire extensible radialement eluant les medicaments

Country Status (4)

Country Link
EP (1) EP1439868A2 (fr)
JP (1) JP2005507710A (fr)
CA (1) CA2465517C (fr)
WO (1) WO2003037397A2 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004357986A (ja) * 2003-06-05 2004-12-24 Terumo Corp ステントおよびステントの製造方法
WO2005063319A1 (fr) * 2003-12-24 2005-07-14 Novartis Ag Compositions pharmaceutiques
US9682175B2 (en) 2004-09-28 2017-06-20 Atrium Medical Corporation Coating material and medical device system including same
US9801913B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Barrier layer
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9827352B2 (en) 2004-09-28 2017-11-28 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
WO2018082278A1 (fr) * 2016-11-04 2018-05-11 先健科技(深圳)有限公司 Endoprothèse vasculaire
US10238891B2 (en) 2012-08-24 2019-03-26 Boston Scientific Corporation Device and method for improving brachytherapy
US10285964B2 (en) 2009-03-10 2019-05-14 Atrium Medical Corporation Fatty-acid based particles
US10322213B2 (en) 2010-07-16 2019-06-18 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
US10543379B2 (en) 2015-10-23 2020-01-28 Boston Scientific Scimed, Inc. Radioactive stents
US10772995B2 (en) 2004-09-28 2020-09-15 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US10864304B2 (en) 2009-08-11 2020-12-15 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
WO2021081360A1 (fr) * 2019-10-24 2021-04-29 Atrium Medical Corporation Dispositif de fixation endovasculaire
US11083823B2 (en) 2005-09-28 2021-08-10 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
CN115671407A (zh) * 2022-10-25 2023-02-03 赛诺神畅医疗科技有限公司 一种自膨式药物洗脱支架系统及其制备方法
WO2024067402A1 (fr) * 2022-09-30 2024-04-04 深圳市先健纬康科技有限公司 Endoprothèse vasculaire

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024448A1 (en) * 2002-08-05 2004-02-05 Chang James W. Thermoplastic fluoropolymer-coated medical devices
US8574627B2 (en) 2006-11-06 2013-11-05 Atrium Medical Corporation Coated surgical mesh
CA2626030A1 (fr) 2005-10-15 2007-04-26 Atrium Medical Corporation Gels hydrophobes reticules pour revetements bioabsorbables de vecteur de medicament
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5928279A (en) * 1996-07-03 1999-07-27 Baxter International Inc. Stented, radially expandable, tubular PTFE grafts
WO2000040278A1 (fr) * 1998-12-31 2000-07-13 Angiotech Pharmaceuticals, Inc. Protheses endovasculaires a revetements bioactifs
US6224626B1 (en) * 1998-02-17 2001-05-01 Md3, Inc. Ultra-thin expandable stent
US6241719B1 (en) * 1999-05-13 2001-06-05 Micro Therapeutics, Inc. Method for forming a radioactive stent
US6254632B1 (en) * 2000-09-28 2001-07-03 Advanced Cardiovascular Systems, Inc. Implantable medical device having protruding surface structures for drug delivery and cover attachment
WO2002024247A1 (fr) * 2000-09-22 2002-03-28 Kensey Nash Corporation Protheses d'administration de medicaments et procedes d'utilisation
WO2002047582A2 (fr) * 2000-12-14 2002-06-20 Reva Medical, Inc. Extenseur dilatable comportant des elements de coulissement et de verrouillage radial

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5928279A (en) * 1996-07-03 1999-07-27 Baxter International Inc. Stented, radially expandable, tubular PTFE grafts
US6224626B1 (en) * 1998-02-17 2001-05-01 Md3, Inc. Ultra-thin expandable stent
WO2000040278A1 (fr) * 1998-12-31 2000-07-13 Angiotech Pharmaceuticals, Inc. Protheses endovasculaires a revetements bioactifs
US6241719B1 (en) * 1999-05-13 2001-06-05 Micro Therapeutics, Inc. Method for forming a radioactive stent
WO2002024247A1 (fr) * 2000-09-22 2002-03-28 Kensey Nash Corporation Protheses d'administration de medicaments et procedes d'utilisation
US6254632B1 (en) * 2000-09-28 2001-07-03 Advanced Cardiovascular Systems, Inc. Implantable medical device having protruding surface structures for drug delivery and cover attachment
WO2002047582A2 (fr) * 2000-12-14 2002-06-20 Reva Medical, Inc. Extenseur dilatable comportant des elements de coulissement et de verrouillage radial

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004357986A (ja) * 2003-06-05 2004-12-24 Terumo Corp ステントおよびステントの製造方法
WO2005063319A1 (fr) * 2003-12-24 2005-07-14 Novartis Ag Compositions pharmaceutiques
US10016465B2 (en) 2004-09-28 2018-07-10 Atrium Medical Corporation Cured gel and method of making
US9682175B2 (en) 2004-09-28 2017-06-20 Atrium Medical Corporation Coating material and medical device system including same
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9827352B2 (en) 2004-09-28 2017-11-28 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US11793912B2 (en) 2004-09-28 2023-10-24 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US10814043B2 (en) 2004-09-28 2020-10-27 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US10792312B2 (en) 2004-09-28 2020-10-06 Atrium Medical Corporation Barrier layer
US9801913B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Barrier layer
US10772995B2 (en) 2004-09-28 2020-09-15 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US10869902B2 (en) 2004-09-28 2020-12-22 Atrium Medical Corporation Cured gel and method of making
US11083823B2 (en) 2005-09-28 2021-08-10 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US10285964B2 (en) 2009-03-10 2019-05-14 Atrium Medical Corporation Fatty-acid based particles
US11166929B2 (en) 2009-03-10 2021-11-09 Atrium Medical Corporation Fatty-acid based particles
US10864304B2 (en) 2009-08-11 2020-12-15 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US11097035B2 (en) 2010-07-16 2021-08-24 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
US10322213B2 (en) 2010-07-16 2019-06-18 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
US10888617B2 (en) 2012-06-13 2021-01-12 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US10238891B2 (en) 2012-08-24 2019-03-26 Boston Scientific Corporation Device and method for improving brachytherapy
US10543379B2 (en) 2015-10-23 2020-01-28 Boston Scientific Scimed, Inc. Radioactive stents
WO2018082278A1 (fr) * 2016-11-04 2018-05-11 先健科技(深圳)有限公司 Endoprothèse vasculaire
US11497636B2 (en) 2016-11-04 2022-11-15 Lifetech Scientific (Shenzhen) Co. Ltd. Vascular stent
WO2021081360A1 (fr) * 2019-10-24 2021-04-29 Atrium Medical Corporation Dispositif de fixation endovasculaire
WO2024067402A1 (fr) * 2022-09-30 2024-04-04 深圳市先健纬康科技有限公司 Endoprothèse vasculaire
CN115671407A (zh) * 2022-10-25 2023-02-03 赛诺神畅医疗科技有限公司 一种自膨式药物洗脱支架系统及其制备方法
CN115671407B (zh) * 2022-10-25 2024-01-30 赛诺神畅医疗科技有限公司 一种自膨式药物洗脱支架系统及其制备方法

Also Published As

Publication number Publication date
CA2465517C (fr) 2011-08-23
CA2465517A1 (fr) 2003-05-08
JP2005507710A (ja) 2005-03-24
EP1439868A2 (fr) 2004-07-28
WO2003037397A3 (fr) 2003-09-18

Similar Documents

Publication Publication Date Title
US20020042645A1 (en) Drug eluting radially expandable tubular stented grafts
CA2465517C (fr) Greffes a stent tubulaire extensible radialement eluant les medicaments
CA2259543C (fr) Greffes tubulaires en ptfe dilatables radialement et pourvues d'un extenseur
US5549663A (en) Endoprosthesis having graft member and exposed welded end junctions, method and procedure
US6979347B1 (en) Implantable drug delivery prosthesis
US8414814B2 (en) Temporal intraluminal stent, methods of making and using
US20120277844A1 (en) Biodegradable Drug Eluting stent Pattern
US11129704B2 (en) Single layer ePTFE and discrete bio-resorbable rings
US20050187607A1 (en) Drug delivery device
US20060178727A1 (en) Hybrid amorphous metal alloy stent
US20030153901A1 (en) Drug delivery panel
US20050113909A1 (en) Polymer coated stents
KR102602555B1 (ko) 나선형 초저 포어쇼트닝 스텐트
AU2011265474B2 (en) Temporal intraluminal stent, methods of making and using
EP3917587A1 (fr) Endoprothèse vasculaire couverte servant à l'administration locale de médicament
MXPA97007888A (en) Implante de estenosis ("stent") coated for the release of farma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002780558

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2465517

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003539736

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002780558

Country of ref document: EP